checkpoint inhibitor — grants

Sort

10,766 grants matching “checkpoint inhibitor”

PHOSPHORYLATION AND FUNCTION OF INHIBITOR 2

$177,582

University Of Virginia Charlottesville · R01 · FY2000 · GM

Stimuli-responsive Delivery of Ectonucleotidase Inhibitors to Reprogram Immunometabolism in Head and Neck Cancer

$177,534

Xin Ming · Wake Forest University Health Sciences · R21 · FY2023 · CA

Role of ATM in Cardiac Myocyte Loss and Myocardial Remodeling

$177,500

Krishna Singh · East Tennessee State University · R21 · FY2009 · HL

Examination of Elm1, polarity, and endocytosis for regulation of cellular morphogenesis in budding yeast

$177,195

Joseph Ronald Marquardt · Western Kentucky University · R16 · FY2025 · GM

Dissecting mechanisms of immunotherapy resistance in melanoma patients

$177,120

Benjamin Izar · Dana-Farber Cancer Inst · K08 · FY2018 · CA

Overcoming drug resistance in metastatic castration resistant prostate cancer with a novel combination of TGF-beta inhibition and enzalutamide

$177,120

Channing Paller · Johns Hopkins University · K23 · FY2017 · CA

Overcoming drug resistance in metastatic castration resistant prostate cancer with a novel combination of TGF-beta inhibition and enzalutamide

$177,120

Channing Paller · Johns Hopkins University · K23 · FY2016 · CA

Investigating the effect of ERCC2 mutations on DNA repair capacity and chemo-radiotherapy response in muscle-invasive bladder cancer

$177,120

Kent W Mouw · Dana-Farber Cancer Inst · K08 · FY2019 · CA

Overcoming drug resistance in metastatic castration resistant prostate cancer with a novel combination of TGF-beta inhibition and enzalutamide

$177,120

Channing Paller · Johns Hopkins University · K23 · FY2018 · CA

Dissecting mechanisms of immunotherapy resistance in melanoma patients

$177,120

Benjamin Izar · Dana-Farber Cancer Inst · K08 · FY2017 · CA

Investigating the effect of ERCC2 mutations on DNA repair capacity and chemo-radiotherapy response in muscle-invasive bladder cancer

$177,120

Kent W Mouw · Dana-Farber Cancer Inst · K08 · FY2017 · CA

Clinical and Translational Investigations of Immune Suppression and Immune Modulation in Glioblastoma

$177,113

Edjah Nduom · National Institute Of Neurological Disorders And Stroke · ZIA · FY2021 · NS

Wwox and Fhit loss and the DNA damage response in breast cancer subtypes

$177,099

Kay Huebner · Ohio State University · R01 · FY2009 · CA

The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer

$177,085

Robert C Bast · University Of Tx Md Anderson Can Ctr · P50 · FY2024 · CA

The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer

$177,085

Anil K Sood · University Of Tx Md Anderson Can Ctr · P50 · FY2025 · CA

The SIK2 Inhibitor GRN-300 enhances PARP Inhibitor sensitivity and overcomes resistance by blocking homologous recombination (HR) DNA repair in ovarian cancer

$177,085

Anil K Sood · University Of Tx Md Anderson Can Ctr · P50 · FY2024 · CA

Targeting Liver-X-Receptor Regulation of Prostate Cancer Immune-Evasion

$177,066

Ian Mitchelle Sayo De Vera · Saint Louis University · R21 · FY2021 · CA

Discovery of fused heterocyclic pyrazine based novel anti-mitotic agents for metastatic melanoma

$177,058

Souvik Banerjee · Middle Tennessee State University · R16 · FY2024 · GM

Direct therapeutic intervention of the tumor microenvironment with a potent inhibitor of fibronectin assembly

$176,980

Suzanne Marie Ponik · University Of Wisconsin-Madison · R21 · FY2021 · CA

Targeting of eIF4A along with immunotherapy to overcome chemoresistance

$176,961

Dayanidhi Raman · University Of Toledo Health Sci Campus · R21 · FY2023 · CA

Investigating the effect of ERCC2 mutations on DNA repair capacity and chemo-radiotherapy response in muscle-invasive bladder cancer

$176,947

Kent W Mouw · Dana-Farber Cancer Inst · K08 · FY2020 · CA

Investigating the effect of ERCC2 mutations on DNA repair capacity and chemo-radiotherapy response in muscle-invasive bladder cancer

$176,947

Kent W Mouw · Dana-Farber Cancer Inst · K08 · FY2021 · CA

PHOSPHORYLATION AND FUNCTION OF INHIBITOR 2

Stimuli-responsive Delivery of Ectonucleotidase Inhibitors to Reprogram Immunometabolism in Head and Neck Cancer

Role of ATM in Cardiac Myocyte Loss and Myocardial Remodeling

Examination of Elm1, polarity, and endocytosis for regulation of cellular morphogenesis in budding yeast

Dissecting mechanisms of immunotherapy resistance in melanoma patients

Overcoming drug resistance in metastatic castration resistant prostate cancer with a novel combination of TGF-beta inhibition and enzalutamide

Overcoming drug resistance in metastatic castration resistant prostate cancer with a novel combination of TGF-beta inhibition and enzalutamide

Investigating the effect of ERCC2 mutations on DNA repair capacity and chemo-radiotherapy response in muscle-invasive bladder cancer

Overcoming drug resistance in metastatic castration resistant prostate cancer with a novel combination of TGF-beta inhibition and enzalutamide

Dissecting mechanisms of immunotherapy resistance in melanoma patients

Investigating the effect of ERCC2 mutations on DNA repair capacity and chemo-radiotherapy response in muscle-invasive bladder cancer

Clinical and Translational Investigations of Immune Suppression and Immune Modulation in Glioblastoma

Wwox and Fhit loss and the DNA damage response in breast cancer subtypes

The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer

The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer

The SIK2 Inhibitor GRN-300 enhances PARP Inhibitor sensitivity and overcomes resistance by blocking homologous recombination (HR) DNA repair in ovarian cancer

Targeting Liver-X-Receptor Regulation of Prostate Cancer Immune-Evasion

Discovery of fused heterocyclic pyrazine based novel anti-mitotic agents for metastatic melanoma

Direct therapeutic intervention of the tumor microenvironment with a potent inhibitor of fibronectin assembly

Targeting of eIF4A along with immunotherapy to overcome chemoresistance

Investigating the effect of ERCC2 mutations on DNA repair capacity and chemo-radiotherapy response in muscle-invasive bladder cancer

Investigating the effect of ERCC2 mutations on DNA repair capacity and chemo-radiotherapy response in muscle-invasive bladder cancer

Mechanisms of Thyroid Autoimmunity in Checkpoint Immunotherapy

Durvalumab in Combination with Olaparib in Non-Small Cell Lung Cancer

Anti-PD-L1-TGFb antibody (M7824) in advanced Non-Small Cell Lung Cancer